Le Lézard
Classified in: Health, Science and technology, Business
Subjects: ERN, CCA, ERP

Halozyme Reports Third Quarter 2019 Results


SAN DIEGO, Nov. 12, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the third quarter ended September 30, 2019 and provided an update on its recent corporate activities and outlook.

"We have transitioned our strategy to focus solely on our high-growth, high-margin ENHANZE® drug delivery technology," said Dr. Helen Torley, president and chief executive officer. "With profitability anticipated in the second quarter of 2020 and a long runway for growth with ENHANZE®, we are in a strong position to build value and return capital to investors."

Third Quarter 2019 and Recent Highlights Include:

Third Quarter 2019 Financial Highlights

Financial Outlook for 2019

Halozyme is updating its 2019 financial guidance ranges:

Webcast and Conference Call
Halozyme will webcast its Quarterly Update Conference Call for the third quarter of 2019 today, Tuesday, November 12, 2019 at 4:30 p.m. ET/1:30 p.m. PT. Dr. Torley will lead the call, which will be webcast live through the "Investors" section of Halozyme's corporate website and a replay will be available following the close of the call. To access the webcast and additional documents related to the call, please visit halozyme.com approximately fifteen minutes prior to the call to register, download and install any necessary audio software. The call may also be accessed by dialing (877) 824-0907 (domestic callers) or (647) 689-5655 (international callers). A telephone replay will be available after the call by dialing (800) 585-8367 (domestic callers) or (416) 621-4642 (international callers) using replay ID number 6597916.

About Halozyme

Halozyme Therapeutics is a biotechnology company focused on novel biological and drug delivery approaches. Halozyme's proprietary enzyme rHuPH20 is used to facilitate the delivery of injected drugs and fluids and potentially reduce the treatment burden of other drugs to patients. Halozyme has licensed its rHuPH20 technology, called ENHANZE®, to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion and argenx. Halozyme derives revenues from these collaborations in the form of milestones and royalties as the Company's partners make progress developing and commercializing their products being developed with ENHANZE®. Halozyme is headquartered in San Diego. For more information visit www.halozyme.com.

Safe Harbor Statement

In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning the Company's future financial performance including expectations for profitability and reduced expenses, plans to implement an organizational restructuring including anticipated reductions in employee headcount, plans to focus its operations solely on its ENHANZE® drug delivery technology, and the Company's plans to initiate a share repurchase program.  Forward-looking statements regarding the Company's ENHANZE® drug delivery technology may include potential growth of the ENHANZE® business, the possible activity, benefits and attributes of ENHANZE®, the possible method of action of ENHANZE®, its potential application to aid in the dispersion and absorption of other injected therapeutic drugs, the number of collaborative targets actually chosen, whether such products are ultimately developed or commercialized, whether milestones triggering milestone payments will be achieved, and statements concerning facilitating more rapid delivery of injectable medications through subcutaneous delivery that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including unexpected fluctuations or changes in revenues, including revenues from collaborators, unexpected delays or results of the Company's organizational restructuring, unexpected expenditures and costs, unexpected delays in the execution of the planned share repurchase, unexpected results or delays in the growth of the Company's ENHANZE® business, unexpected results or delays in the development and regulatory review of ENHANZE® products, regulatory approval requirements, unexpected adverse events and competitive conditions.

Contact:
Al Kildani
Vice President, Investor Relations and Corporate Communications
858-704-8122
ir@halozyme.com

Halozyme Therapeutics, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

(In thousands, except per share amounts)




Three Months Ended


Nine Months Ended



2019


2018


2019


2018

Revenues:









Royalties


$

16,609



$

18,710



$

52,669



$

59,643


Product sales, net


29,205



6,269



43,355



17,553


Revenues under collaborative agreements


416



577



46,303



14,434


Total revenues


46,230



25,556



142,327



91,630


Operating expenses:









Cost of product sales


22,333



626



28,859



4,514


Research and development


30,455



35,540



95,693



113,602


Selling, general and administrative


17,979



14,864



53,323



42,773


Total operating expenses


70,767



51,030



177,875



160,889


Operating loss


(24,537)



(25,474)



(35,548)



(69,259)


Other income (expense):









Investment and other income, net


1,613



1,910



5,653



5,561


Interest expense


(2,078)



(4,286)



(7,896)



(14,286)


Net loss before income taxes


(25,002)



(27,850)



(37,791)



(77,984)


Income tax expense


13



?



52



220


Net loss


$

(25,015)



$

(27,850)



$

(37,843)



$

(78,204)











Net loss per share:









Basic and diluted


$

(0.17)



$

(0.19)



$

(0.26)



$

(0.55)











Shares used in computing net loss per share:









Basic and diluted


146,136



143,949



145,435



143,396


 

Halozyme Therapeutics, Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

(In thousands)




September 30,
2019


December 31,
2018

ASSETS





Current assets:





Cash and cash equivalents


$

59,202



$

57,936


Marketable securities, available-for-sale


178,796



296,590


Accounts receivable, net


40,744



30,005


Inventories


36,051



22,625


Prepaid expenses and other assets


27,248



20,693


Total current assets


342,041



427,849


Property and equipment, net


15,398



7,465


Prepaid expenses and other assets


12,417



4,434


Restricted cash


500



500


Total assets


$

370,356



$

440,248







LIABILITIES AND STOCKHOLDERS' EQUITY





Current liabilities:





Accounts payable


$

4,314



$

4,079


Accrued expenses


45,679



49,529


Deferred revenue, current portion


3,511



4,247


Current portion of long-term debt, net


54,537



91,506


Total current liabilities


108,041



149,361







Deferred revenue, net of current portion


1,247



5,008


Long-term debt, net


9,308



34,874


Other long-term liabilities


6,407



2,118







Stockholders' equity:





Common stock


147



145


Additional paid-in capital


814,095



780,457


Accumulated other comprehensive income (loss)


392



(277)


Accumulated deficit


(569,281)



(531,438)


Total stockholders' equity


245,353



248,887


Total liabilities and stockholders' equity


$

370,356



$

440,248


 

Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

 

SOURCE Halozyme Therapeutics, Inc.


These press releases may also interest you

at 09:50
A national survey released today by PLUS Communications and GS Strategy Group finds that heading into a divisive presidential election year, customers want businesses to focus on taking care of their employees over pursuing politically-motivated...

at 09:48
Sagicor® Life Insurance Company (Sagicor) introduces its WealthCare Indexed Single Premium Universal Life Insurance, a policy designed for the changing financial needs of Baby Boomers. As this generation continues to transition into retirement, their...

at 09:47
MICT, Inc. (the "Company") announced today that it has filed a preliminary proxy statement with the U.S. Securities and Exchange Commission (the SEC) relating to, among other items, its planned acquisition of Global Fintech Holdings Ltd (GFH), and a...

at 09:42
For The Biome, the Vermont-based wellness and skincare company launched last year by Paul and Barbi Schulick, has announced a partnership with the JHCapital family office of Jim Crook and Allison Maino. With over 35 years of leadership experience and...

at 09:42
Aflac Incorporated today announced that it is one of 325 companies across 50 industries included in the 2020 Bloomberg Gender-Equality Index (GEI). This is the first year that Aflac participated in the survey to become part of this prestigious index....

at 09:41
BIDITUP Auctions and Appraisals Worldwide and Maynards, global leaders in asset conversion are announcing that assets from two locations of Montebello Container Company will soon be coming to auction. Montebello Container Company was founded in 1966...



News published on 12 november 2019 at 16:01 and distributed by: